

References:

1. Loosen PT, Shelton RC. Mood Disorders. In: Ebert MH, Leckman JF, Petrakis IL. *Current Diagnosis & Treatment: Psychiatry, 3e*. New York, NY: McGraw-Hill; <https://accessmedicine-mhmedical-com.arcadia.idm.oclc.org/content.aspx?bookid=2509§ionid=200804247>
2. Locher C, Koechlin H, Zion SR, et. al. Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo for common psychiatric disorders among children and adolescents. *JAMA Psychiatry*. 2017;74(10): 1011-1020. url: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5667359/>
3. Ferguson JM. SSRI antidepressant medications: adverse effects and tolerability. *Prim Care Companion J Clin Psychiatry*. 2001;3(1): 22-27. url: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC181155/>
4. Tylee A, Walters P. Onset of action of antidepressants. *BMJ*. 2007;334(7600): 911-912. doi: 10.1136/bmj.39197.619190.80
5. Studerus E, Kommer M, Hasler F, et. al. Acute, subacute and long-term subjective effects of psilocybin in healthy humans: a pooled analysis of experimental studies. *J Psychopharmacol*. 2010;25(11): 1434-1452. doi: 10.1177/0269881110382466
6. Grob CS, Danforth AL, Chopra GS, et. al. Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer. *Arch Gen Psychiatry*. 2011;68(1): 71-78. doi: 10.1001/archgenpsychiatry.2010.116
7. Carhart-Harris RL, Bolstridge M, Rucker J. Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. *Lancet Psychiatry*. 2016;3(7): 619-627. doi: 10.1016/S2215-0366(16)30065-7

8. Erritzoe D, Roseman L, Nour MM. Effects of psilocybin therapy on personality structure. *Acta Psychiatr Scand.* 2018;138(5): 368-378. doi: 10.1111/acps.12904
9. Carrillo F, Sigman M, Fernandez-Slezak D. Natural speech algorithm applied to baseline interview data can predict which patients will respond to psilocybin for treatment-resistant depression. *J Affect Disord.* 2018;230: 84-86. doi: 10.1016/j.jad.2018.01.006
10. Hendricks PS, Johnson MW, Griffiths RR. Psilocybin, psychological distress, and suicidality. *J Psychopharmacol.* 2015;29(9): 1041-1043. doi: 10.1177/0269881115598338
11. Carhart-Harris RL, Roseman L, Bolstridge M. Psilocybin for treatment-resistant depression: fMRI-measured brain mechanisms. *Sci Rep.* 2017;7. doi: 10.1038/s4159-017-13282-7
12. Hendricks PS, Thorne CB, Clark CB. Classic psychedelic use is associated with reduced psychological distress and suicidality in the United States adult population. *J Psychopharmacol.* 2015;29(3): 280-288. doi: 10.1177/0269881114565653.
13. Rucker J, Jelen L A, Flynn S. Psychedelics in the treatment of unipolar mood disorders: a systematic review. *J Psychopharmacol.* 2016;30(12): 1220-1229. doi: 10.1177/0269881116679368